ReviewDrugs2014
New approaches to antiretroviral drug delivery: challenges and opportunities associated with the use of long-acting injectable agents.
Review in Drugs, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Injectable long acting antiretroviral for HIV treatment and prevention: perspectives of potential users.BMC infectious diseases · 2023Article
- Modeling the health impact and cost threshold of long-acting ART for adolescents and young adults in Kenya.EClinicalMedicine · 2020Article
- Synthesis and characterization of a long-acting emtricitabine prodrug nanoformulation.International journal of nanomedicine · 2019Article
- Injectable long-acting human immunodeficiency virus antiretroviral prodrugs with improved pharmacokinetic profiles.International journal of pharmaceutics · 2018Article
- Qualitative Consumer Research on Acceptance of Long-Acting Pre-Exposure Prophylaxis Products Among Men Having Sex with Men and Medical Practitioners in the United States.AIDS research and human retroviruses · 2018Article
- Long-acting injectable atovaquone nanomedicines for malaria prophylaxis.Nature communications · 2018Article
- Long acting systemic HIV pre-exposure prophylaxis: an examination of the field.Drug delivery and translational research · 2017Review
- The Vaginal Microbiome and its Potential to Impact Efficacy of HIV Pre-exposure Prophylaxis for Women.Current HIV/AIDS reports · 2017Review
- Of Mice, Macaques, and Men: Broadly Neutralizing Antibody Immunotherapy for HIV-1.Cell host & microbe · 2017Review
- Preferences for Long-Acting Pre-exposure Prophylaxis (PrEP), Daily Oral PrEP, or Condoms for HIV Prevention Among U.S. Men Who Have Sex with Men.AIDS and behavior · 2017Article
- The mixed lineage kinase-3 inhibitor URMC-099 improves therapeutic outcomes for long-acting antiretroviral therapy.Nanomedicine : nanotechnology, biology, and medicine · 2016Article
- Tenofovir-based oral preexposure prophylaxis prevents HIV infection among women.Current opinion in HIV and AIDS · 2016Review
- The Art of HIV Elimination: Past and Present Science.Journal of AIDS & clinical research · 2015Article
- A Shot in the Arm for HIV Prevention? Recent Successes and Critical Thresholds.AIDS research and human retroviruses · 2015Review
- Clinical Treatment Options Infectious Diseases: Update on PrEP Implementation, Adherence, and Advances in Delivery.Current treatment options in infectious diseases · 2015Article
- Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV.Clinical pharmacokinetics · 2015Article
- Opposing regulation of endolysosomal pathways by long-acting nanoformulated antiretroviral therapy and HIV-1 in human macrophages.Retrovirology · 2015Article
- PrEP Implementation Science: State-of-the-Art and Research Agenda.Journal of the International AIDS Society · 2015Article
- Hyperbranched polydendrons: a new nanomaterials platform with tuneable permeation through model gut epithelium.Chemical science · 2015Article
- The promises and challenges of pre-exposure prophylaxis as part of the emerging paradigm of combination HIV prevention.Journal of the International AIDS Society · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Research on improved treatment of HIV infection and pre-exposure prophylaxis continues. Poor adherence to treatment is the critical risk factor for virological failure and resistance development, and long-acting formulations of anti-HIV medications that need only infrequent dosing may facilitate long-term therapeutic responses. Importantly, long-acting formulations of therapeutic agents have been used to avoid missing doses or treatment fatigue to prescribed lifelong medications in a number of different medical fields, with demonstrable success. However, such formulations are associated with challenges, such as the prolongation of adverse events with the persistence of drug concentrations and concerns over the development of resistance as a result of selective pressure as drug concentrations decline. Furthermore, long-acting injectable formulations of antiretroviral (ARV) agents with infrequent dosing may be advantageous over daily oral drug intake to prevent transmission of HIV. However, the knowledge on protective drug concentrations and frequency of dosing is poor to date and implementation globally is challenging. Importantly, if nanoformulations of ARVs requiring lower drug doses become available globally, the potential for treatment cost reductions is high, as, especially in resource-limited settings, the active pharmaceutical ingredient accounts for the greater proportion of the total cost of the medicine. In conclusion, different long-acting ARVs are being studied in phase I/II for both the treatment and prevention of HIV infection, and research on administering these agents in combination has started.
Indexed as
Identifiers
24327298What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.